BioAlliance receives European patent for Livatag to treat primary liver cancer

BioAlliance Pharma SA (Euronext Paris: BIO), a company dedicated to specialty and orphan oncology products, today announces the grant of a European patent protecting its Transdrug™ nanotechnology. This new industrial property notably covers Livatag^®, the first product of its Orphan oncology products portfolio until 2023.

A phase III clinical trial application for Livatag^® in primary liver cancer has been submitted on June 27, 2011. This treatment based on the Transdrug™ nanoparticles delivery system delivers doxorubicin into the resistant tumor cell, overcoming multi-drug resistance mechanisms. These mechanisms are very frequent in some cancers, occurring either spontaneously or following a first treatment. The primary liver cancer, third leading cause of death by cancer worldwide, is spontaneously chemo resistant.

"Livatag^® is already protected until 2019 by a first family of worldwide granted patents covering the Transdrug™ technology. The grant of this second European patent considerably strengthens the industrial property of Livatag^® and completes the market exclusivity given by the orphan status, thus reinforcing the value of this key asset for the Company," comments Judith Greciet, CEO of BioAlliance Pharma.